Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gradient hyperfractionated vs conventional fractionated IMRT with concurrent chemoradioimmunotherapy for locally advanced nasopharyngeal carcinoma after non-response to neoadjuvant chemoimmunotherapy
ChiCTR2500115847Phase 2Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cisplatin, gemcitabine, docetaxel and paclitaxel in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free Survival (PFS). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
cisplatingemcitabinedocetaxelpaclitaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500115847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115847.